Cooley advised Calithera Biosciences on its $80.5 million shelf-takedown offering of 7,854,500 shares of common stock, which includes the full exercise of the underwriters’ option to…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
